Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 3
2008 2
2009 1
2010 3
2011 4
2012 1
2013 3
2014 3
2015 1
2017 1
2018 2
2019 1
2021 4
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: warner sl. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. Sakemura RL, et al. Among authors: warner sl. Cancer Immunol Res. 2023 Sep 1;11(9):1222-1236. doi: 10.1158/2326-6066.CIR-22-0254. Cancer Immunol Res. 2023. PMID: 37378662 Free PMC article.
Activators of PKM2 in cancer metabolism.
Warner SL, Carpenter KJ, Bearss DJ. Warner SL, et al. Future Med Chem. 2014 Jun;6(10):1167-78. doi: 10.4155/fmc.14.70. Future Med Chem. 2014. PMID: 25078136 Review.
Targeting Axl and Mer kinases in cancer.
Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Verma A, et al. Among authors: warner sl. Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20. Mol Cancer Ther. 2011. PMID: 21933973 Review.
Targeting Aurora-2 kinase in cancer.
Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, Daver N, Borthakur G, Battula VL. Tyagi A, et al. Among authors: warner sl. Leukemia. 2024 Jan;38(1):82-95. doi: 10.1038/s41375-023-02086-6. Epub 2023 Nov 25. Leukemia. 2024. PMID: 38007585
28 results